- Home
- NDMO vs CSTL Comparison
NDMO vs CSTL Comparison
Compare NDMO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- CSTL
- Stock Information
- Founded
- NDMO 2019
- CSTL 2007
- Country
- NDMO United States
- CSTL United States
- Employees
- NDMO N/A
- CSTL N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- NDMO Finance
- CSTL Health Care
- Exchange
- NDMO Nasdaq
- CSTL Nasdaq
- Market Cap
- NDMO 633.1M
- CSTL 661.7M
- IPO Year
- NDMO N/A
- CSTL 2019
- Fundamental
- Price
- NDMO $10.61
- CSTL $33.40
- Analyst Decision
- NDMO
- CSTL Strong Buy
- Analyst Count
- NDMO 0
- CSTL 6
- Target Price
- NDMO N/A
- CSTL $38.67
- AVG Volume (30 Days)
- NDMO 218.6K
- CSTL 462.2K
- Earning Date
- NDMO 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- NDMO 6.75%
- CSTL N/A
- EPS Growth
- NDMO N/A
- CSTL N/A
- EPS
- NDMO N/A
- CSTL N/A
- Revenue
- NDMO N/A
- CSTL $343,530,000.00
- Revenue This Year
- NDMO N/A
- CSTL N/A
- Revenue Next Year
- NDMO N/A
- CSTL N/A
- P/E Ratio
- NDMO N/A
- CSTL N/A
- Revenue Growth
- NDMO N/A
- CSTL 10.15
- 52 Week Low
- NDMO $8.99
- CSTL $14.59
- 52 Week High
- NDMO $11.24
- CSTL $35.49
- Technical
- Relative Strength Index (RSI)
- NDMO 52.85
- CSTL 72.48
- Support Level
- NDMO $10.48
- CSTL $32.51
- Resistance Level
- NDMO $10.82
- CSTL $35.49
- Average True Range (ATR)
- NDMO 0.13
- CSTL 1.70
- MACD
- NDMO -0.00
- CSTL 0.56
- Stochastic Oscillator
- NDMO 38.24
- CSTL 82.39
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.